pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
10d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
10d
China has a clear shot to 2030 goals, though economic, cultural barriers remain
biospace
10d
Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
fiercebiotech
10d
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
biospace
11d
Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run
fiercebiotech
11d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
11d
Coherus shrinks headcount 30% to narrow focus of cancer combo
fiercebiotech
11d
Bayer wins FDA nod for a new kind of blood thinner
biopharma dive
11d
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
biospace
11d
Vir hepatitis D drug succeeds in first pivotal study
biopharma dive
11d
Argenx to buy peptide platform in potentially billion-dollar deal
biopharma dive
11d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
11d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
11d
STAT+: Gene therapy’s long-debated cancer risk materializes
stat
12d
Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
fiercebiotech
12d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
12d
Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drug
fiercebiotech
12d
Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
fiercebiotech
12d
Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
fiercebiotech
13d
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
stat
14d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
14d
J&J’s Rybrevant nets FDA approval in head and neck cancer
endpoints
14d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
14d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
15d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
15d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
15d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
15d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
15d
T-Therapeutics reloads with a $133M megaround for bispecifics
biopharma dive
16d
Alethio clinches $90M to advance antibody for essential thrombocythemia
endpoints
← prev
page 3 of 27
next →